
Explore the key conclusions around aiming for higher treatment targets, discussed at the UCB-sponsored Satellite Symposium presented at EULAR 2023.
Professor Nico Wulffraat is a paediatric rheumatologist and immunologist and full professor within the Department of Paediatrics, Subunit Paediatric Immunology and Rheumatology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, The Netherlands.
Professor Wulffraat completed his medical degree at the Free University, Amsterdam, The Netherlands, and was later awarded a PhD from the same institution. His research interests focus on paediatric rheumatology, and he set up the European project Pharmachild and the European project SHARE on clinical guidelines in paediatric rheumatology. Additionally, Professor Wulffraat is the coordinator of the European Reference Network (ERN) RITA.
Professor Wulffraat is a member of committees such as the Gezondheidsraad Advies CVS (chronic fatigue syndrome) and the Evaluatie Beoordeling NFU Expertisecentra. He has also contributed to over 330 peer-reviewed papers.
Watch Prof Frank Behrens discuss the importance of treating skin symptoms in addition to musculoskeletal symptoms for patients with SpA.
Achieving ACR50 is associated with improvements in quality of life for patients with PsA.1 Dive into the data supporting higher treatment targets in clinical...
Watch Prof Lars Erik Kristensen and Prof Frank Behrens discuss how MDA is a realistic treatment target in clinical practice and the barriers to achieving it for...
Treatment for PsA should target a broad range of musculoskeletal and extra-articular manifestations.1 Listen to Assoc. Prof Philipp Sewerin explain how MDA can...
Explore the key conclusions around aiming for higher treatment targets, discussed at the UCB-sponsored Satellite Symposium presented at EULAR 2023.
axSpA is a complex disease with a significant burden on many aspects of daily life.1,2 Dive into the importance of ASAS40 for your patients with Dr Fabian Proft.